Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study

Emre M., Poewe W., De Deyn P. P., Barone P., Kulisevsky J., Pourcher E., ...Daha Fazla

CLINICAL NEUROPHARMACOLOGY, cilt.37, sa.1, ss.9-16, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 37 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1097/wnf.0000000000000010
  • Dergi Adı: CLINICAL NEUROPHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.9-16
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.